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Abstract objectives To present a simple method for estimating population-level anti-retroviral therapy (ART)
need that does not rely on knowledge of past HIV incidence.
methods A new approach to estimating ART need is developed based on calculating age-specific
proportions of HIV-infected adults expected to die within a fixed number of years in the absence of
treatment. Mortality data for HIV-infected adults in the pre-treatment era from five African HIV cohort
studies were combined to construct a life table, starting at age 15, smoothed with a Weibull model.
Assuming that ART should bemade available to anyone expected to die within 3 years, conditional 3-year
survival probabilitieswere computed to represent proportions needingART.Thebuild-upofARTneed in a
successful programmecontinuously recruiting infected adults into treatment as they age towithin3 years of
expected death was represented by annually extending the conditional survival range.
results The Weibull model: survival probability in the infected state from age 15 = exp()0.0073 ·
(age ) 15)1.69) fitted the pooled age-specific mortality data very closely. Initial treatment need for in-
fected persons increased rapidly with age, from 15% at age 20–24 to 32% at age 40–44 and 42% at age
60–64. Overall need in the treatment of naı¨ve population was 24%, doubling within 5 years in a
programme continually recruiting patients entering the high-risk period for dying.
conclusion A reasonable projection of treatment need in an ART naive population can be made based
on the age and gender profile of HIV-infected people.
keywords antiretroviral therapy, lifetable models, AIDS, HIV, cohort studies, mortality, Africa
Introduction
The large number of people living with HIV ⁄AIDS
(PLWHA) in Africa places a huge burden on anti-retroviral
therapy (ART) services. There is a need for simple tools to
estimate treatment need amongst those who do not have
access to ART services, and to gauge whether established
services keep up with local treatment needs. Such estimates
have been made at a national level using complex projec-
tion methods, such as the Spectrum package developed by
UNAIDS (Stover et al. 2006; Mahy et al. 2010), which
estimates the theoretical need for ART by projecting
distributions of expected CD4 counts from an assumed
pattern of past HIV incidence in the population. These
estimates of national need can be compared with estimates
of patients receiving treatment obtained from aggregated
data from the national treatment programme.
National estimates of ART need are difficult to disag-
gregate for regional or district populations, as estimates of
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past incidence are not available at a local level, and because
local prevalence patterns owe as much to different migra-
tory movements by infected and uninfected persons as to
the past incidence history of the locality. We propose a new
approach, whereby the need for ART in HIV positive
persons is estimated from the proportion that would be
expected to die within a fixed number of years in the
absence of treatment. This new method calculates ART
needs specific for gender and age group, taking account of
longer exposure and faster disease progression observed in
older people, and cumulates estimated treatment need
arising from improved survival of those accessing treat-
ment.
The new approach could be applied in any sub-national
population where HIV prevalence estimates are available
from nationally representative population-based surveys
[like the Demographic and Health (DHS) and AIDS
Indicator Surveys (AIS)] that anonymously collect bio-
markers of HIV status. It does not require further specialist
information (such as CD4 count or viral load distributions)
to estimate disease stage at a population level. This new
method should therefore prove particularly useful for
obtaining rough estimates of treatment need in populations
where large proportions have never had HIV counselling
and testing (HCT). It could also be used to estimate
residual treatment need in population sub-groups that have
not yet had any contact with care and treatment pro-
grammes, provided an approximate estimate of their age
pattern of HIV prevalence can be made.
The raw data from which the age-specific mortality rates
of untreated HIV positive persons were calculated was
collected by the ALPHA network study centres (Maher
et al. 2010) prior to ART availability. These mortality
patterns were previously reported (Todd et al. 2007; Zaba
et al. 2007), but the pooled data set has since been
augmented with more pre-treatment era data, and im-
proved analysis methods have been devised to construct
age-specific mortality models for the HIV infected.
Methods
In this analysis, we used data from five sites: Karonga
(Malawi), Kisesa (NIMR, Tanzania), Umkhanykade (the
Africa Centre for Health and Population Studies), Masaka
(MRC ⁄UVRI, Uganda) and Manicaland (BRTI, Zimba-
bwe). Table 1 presents some background characteristics of
the sites contributing data. Further details about each site
are given in the companion papers in this supplement.
Deaths and mortality rates of HIV infected
To estimate mortality rates among HIV-infected persons in
the pre-treatment era, we used information on deaths
occurring in the study areas to residents who were known
to be HIV positive as a result of prior testing. The person-
years at risk corresponding to these deaths were calculated
from observed time since sero-conversion for incident cases
(assumed to be half-way between last negative and first
positive test), and from time since first positive test for
prevalent cases. Periods during which infected persons
were not under observation in the study were censored: left
censored at age 15 or first move into study area; right
censored at loss to follow-up or last interview; and interval
censored if they left the study area and took up residence
elsewhere, but then returned. HIV mortality in the absence
of ART was calculated for periods up until ART became
available in the study area (taken as 1 January 2004 in
Karonga, Umkhanyakude and Kyambaliwa; 1 January
2005 in Kisesa, and 1 July 2006 in Manicaland). The
methods for calculating mortality rates have been fully
described previously (Todd et al. 2007; Zaba et al. 2007).
To calculate numbers in need of treatment at any time
point, we also took account of deaths of residents who had
never had an HIV test, or who had previously tested
negative, but were diagnosed as AIDS deaths following a
verbal autopsy (VA) interview with a family member. For
AIDS deaths diagnosed at VA, subjects were assumed to
Table 1 Background characteristics of study sites contributing data to pooled analysis
Study site Location
Start of HIV (and
demographic) surveillance
Start of ART
availability
Population
size, 2008
2008 HIV
prevalence (%)
Karonga Northern Malawi 2002 2004 32 000 7
Umkhanyakude KwaZulu Natal, S. Africa 2003 (2000) 2004 86 000 22
Kisesa North West Tanzania 1994 2005 28 000 7
Kyambaliwa Southern Uganda 1989 2003 7 000 6
Manicaland Eastern Zimbabwe 1998 2006* 30 000 16
ART, anti-retroviral therapy.
*Manicaland data were provided for the pooled data set up to 2005.
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have been infected for 10 years prior to death, or from
mid-way between last negative test and death, or from date
of entry into observation in the study, whichever of these
dates was later.
Using the pooled data set, an age-based Kaplan–Meier
survival function was constructed to represent mortality
experience of HIV positive adults, with an origin at age 15.
No upper age limit was imposed on the data, but
observations after age 75 are sparse, and so, resulting
graphs and tables are truncated at this age. Non-parametric
tests (log rank and Cox proportional hazards diagnostics)
were performed on the survival data to investigate whether
there were significant differences in mortality levels or age
patterns between study sites and by gender (allowing for
clustering between sites).
Model life-table fitting
Parametric regression techniques as implemented in Stata
version 11 (StataCorp, 2009) were used to fit Weibull
models to represent age-specific mortality among the HIV
infected in the pre-treatment era. This two parameter
model is characterised by k, the overall mortality level and
u, the pattern of increase of mortality with age, to define
P(a), the probability of surviving in the infected state from
age 15 to age a
PðaÞ ¼ expðk  ða  15Þ/Þ: ð1Þ
The probability of dying in the next n years for an HIV-
infected person aged a in a population where ART is not
yet available (i.e. available for 0 years) is thus given by
D(a, n, 0)
Dða; n; 0Þ ¼ 1 Pða þ nÞ
PðaÞ : ð2Þ
Numbers needing treatment
Assuming that the proportion needing ART can be equated
to the proportion expected to die in the next n years in the
absence of ART, this expression provides a way of
estimating treatment need in a population where ART has
not been previously available: n can be thought of as the
mean time from optimal treatment start to expected AIDS
death. In this article, a default value of n = 3 years has
been chosen – to put this choice into perspective and
compare with more complex models, Table 2 shows the
range of assumptions used in current and past versions of
the SPECTRUM model, relating mean or median time
from estimated CD4 thresholds to death.
Table 2 shows that most expositions quote only median
time (not mean time) from CD4 threshold to death; that
the range of estimated values of mean time to death for
commonly used CD4 thresholds (200 and 350) are very
wide (2.6–5.2 years and 5.5–9.8 years respectively) and
that where credibility limits have been estimated these are
also very wide – up to 30% and 300% of the mean value
(Wandel et al. 2008). We suggest that our default value of
n = 3 be regarded as notionally equivalent to a low CD4
threshold of around 200 (as used at the start of most
national ART programmes), whereas the currently pro-
posed CD4 threshold of 350 can be regarded as notionally
equivalent to a value of n = 6.
Anti-retroviral therapy programmes that recruit every-
one who is expected to die in the next n years in the
absence of treatment will need to recruit additional people
in every calendar year as infected cohorts age and more of
them enter into the high death risk period: y years
following the start of the programme, the proportion of
HIV-infected people currently aged a who will need
treatment is D(a, n, y) where
Dða; n; yÞ ¼ 1 Pða þ nÞ
Pða  yÞ : ð3Þ
Strictly speaking, this represents the proportion of
infected people aged a ) y in year 0 who are expected to
need treatment in y year’s time. Applying this to infected
persons aged a in year y is equivalent to assuming that the
mortality of those on treatment can be brought down, on
Table 2 CD4 Estimated median and mean time from CD4 treatment threshold to death
CD4 treatment
initiation threshold
Median time to death in years {figures
in braces are author’s estimates for both
sexes based on 67% infected female}
Mean time to death in years {figures
in braces are author’s estimates based
on median using Poisson approximation} Source
200 1.5 males, 2.0 females {1.83 both sexes} {2.6} Mahy et al. (2010)
200 2.1 {3.0} Stover et al. (2006)
200 2.7 (credibility limits 0.8–8.4) 5.2 (credibility limits 1.5–15.9) Wandel et al. (2008)
275 5.0 (credibility limits 1.6–13.8) 7.4 (credibility limits 2.5–20.5 Wandel et al. (2008)
350 3.6 males, 3.9 females {3.8 both sexes} {5.5} Mahy et al. (2010)
350 4.0 {5.7} Stover et al. (2006)
350 7.6 (credibility limits 3.0–18.3) 9.8 (credibility limits 3.8–23.7) Wandel et al. (2008)
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average, to the same level as the mortality of those HIV-
infected persons originally classified as not yet in need of
treatment.
To calculate the actual number needing treatment, these
proportions are applied to the numerical age distribution
H(a, y) of HIV positive persons identified in the population
in a particular year, allowing for the number of years y that
have passed since the start of ART availability. An
adjustment can be made for persons of unknown HIV
status by assuming that prevalence amongst those of
unknown status is the same as among those whose status is
known in each age group. The overall requirements for
ART, and progress of the programme in meeting ART
needs can be judged by summing the numbers across age
groups, although it may also be useful to monitor trends by
gender and broad age groups to judge which population
sub-groups are less well served. The total number T(y)
needing treatment in year y is given by:
TðyÞ ¼
Xa¼80þ
a¼1519
Dða; n; yÞ  Hða; yÞ: ð4Þ
Equation 4 estimates the total ART need y years after the
start of the programme, in a programme that operates at
maximum efficiency in recruiting each year all the new
patients in need of therapy. Programmes that fail to recruit
all those defined as in need in earlier years will not ‘need’ to
recruit the full quota of patients in later years, because
some of those who should have been recruited from the
high mortality risk group will have died in the intervening
years, so that the proportion in need in later years will be
reduced. We suggest the use of linear interpolation for
estimating R(y + 1), the reduced treatment need in the year
y + 1 based on the actual proportion receiving treatment in
year y, R(y).
Suppose the actual proportion treated in year y, R(y), is
related to the maximum theoretical need T(z) in an earlier
year z, according to T(z) £ R(y) £ T(z + 1) where y ‡ z.
The linear interpolation estimate for the reduced need in
year y + 1 is given by:
Rðy þ 1Þ ¼ Tðz þ 1Þ  RðyÞ
Tðz þ 1Þ  TðzÞ  Tðz þ 1Þ
þ RðyÞ  TðzÞ
Tðz þ 1Þ  TðzÞ  Tðz þ 2Þ:
ð5Þ
Results
Mortality patterns in HIV infected
A summary of the basic data on mortality of HIV-infected
persons contributed by each study site is shown in
Table 3. Umkhanyakude in South Africa contributed the
largest number of observations and along with Karonga
in Malawi (which contributed the fewest observations)
experienced higher crude death rates; Kisesa and Man-
icaland experienced lower death rates amongst the HIV
infected.
The inter-site differences are fairly small and insignifi-
cant compared with other mortality differentials – e.g. by
sex: the crude death rate for HIV-infected men pre-ART
was 110.2 per thousand (104.7–116.0), for women 75.9
(72.5–79.5); by infection status: uninfected 5.1 (4.8–5.4),
unknown status 21.5 (20.8–22.4). In the 3 years following
the introduction of ART, the crude death rate for HIV-
infected persons across all sites fell from 88.2 (85.2–91.3)
to 64.3 per thousand (61.9–66.9).
Differences in crude death rates may be due to the age
structure of the infected populations, as mortality amongst
the HIV infected rises rapidly with age, and the age
structure of the HIV infected varies according to the
maturity of the epidemic and the overall age structure of
the population. It is therefore appropriate to compare age-
specific survival patterns, as in Figure 1, which shows
age-based Kaplan–Meier functions in the HIV-infected
study populations based on pre-ART mortality.
Table 3 Deaths, person-years of observation and crude death rates in HIV positive population in five ALPHA network sites, pre-ART
roll-out
Study site
Number of deaths
of HIV infected
Person-years observation of
HIV infected (thousands)
Crude death rate among
HIV infected (per thousand)
95% confidence
intervals
Karonga 70 0.663 105.5 83.5 133.4
Umkhanyakude 1865 19.311 96.6 92.3 101.1
Kisesa 322 4.389 73.4 65.8 81.8
Kyambaliwa 534 6.157 86.7 79.7 94.4
Manicaland 495 6.736 73.5 67.3 80.3
Total 3286 37.255 88.2 85.2 91.3
ART, anti-retroviral therapy.
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Non-parametric Cox regression results suggested that
the differences between sites were not important, once the
age structure of the infected population in the different
sites was accounted for. Between ages 25 and 50, where
80% of AIDS deaths occur, compared with Karonga,
hazard ratios were Umkhanyakude 1.22 (0.92–1.63),
Kisesa 0.99 (0.73–1.34), Kyambuliwa 1.07 (0.80–1.44)
and Manicaland 0.83 (0.62–1.11), and proportional
hazard assumptions were satisfied (chi squared statistic test
on Schoenfeld residuals with four degrees of freedom is
4.41, P = 0.3530).
A Weibull parametric model was fitted to the pooled
mortality data for both sexes to obtain a mathematical
representation of conditional survival of HIV-infected
persons by age – Figure 2 shows that this model is an
excellent fit to the observed data (r2 = 0.9992 comparing
Kaplan–Meier and Weibull at all ages for which deaths
were reported). The parameters for the best fitting regres-
sion model were k = 0.0073 (95% CI: 0.0059–0.0091) and
u = 1.69 (95% CI: 1.59–1.79). The curve representing the
model fitting is obtained by substituting these values in
Eqn 1.
ART treatment need by age and programme year
The mortality pattern described by the Weibull model
was used to predict the proportions expected to die
within 3 years in a treatment naive population, using Eqn
2 with n = 3. The results are shown in the first column of
Table 2, averaged over 5 year age groups. The remaining
columns show the maximum theoretical treatment need
during each of the 5 years following the start of the
programme. The entries show the proportion of currently
infected persons needing treatment in each age group,
obtained by applying Eqn 3 with n = 3, and y as
indicated by the column heading. At the start of the
programme, the proportion of HIV-infected persons
needing treatment in the 20–24, 40–44 and 60–64 age
groups would be 15%, 32% and 40%, respectively, and
this would rise to 30%, 61% and 75% of the currently
infected in the respective age groups, after 5 years of the
programme.
The last three rows show the overall proportion of
infected persons needing treatment when the age-specific
proportions are applied to the average age distributions of
infected persons, by gender, in the pooled data contributed
by sites since start of surveillance. As the need for
treatment escalates rapidly with age, the overall proportion
of infected women needing treatment is lower than for
men, because the age distribution of infected women is
younger. A treatment programme that succeeded in
restoring those otherwise facing death in the next 3 years
to the same level of mortality experienced by those outside
the high risk group, and which continued to recruit onto
treatment all those entering the high risk group over the
coming years would need to grow rapidly, almost doubling
in size within 5 years.
We can explore the scale and trend of ART needs in
programmes with different theoretical recruitment strat-
egies using different values of n (the time from treatment
start to expected AIDS death) in Eqns 2 and 3. The
bottom line of Table 4 shows that the overall starting
need for ART in a programme that aimed to recruit those
expected to die within 3 years would be 24%, almost
doubling to 46.5% in 5 years in a population whose HIV
prevalence pattern by age was the average of that
observed in the ALPHA sites. If a less ambitious
programme only aimed to recruit those who were
expected to die within a year, the overall proportion
0.
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Figure 1 Survival from age 15 for HIV-infected persons in five
ALPHA network sites, pre-anti-retroviral therapy roll-out.
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Figure 2 Observed survival pattern for HIV positive pre-
anti-retroviral therapy in pooled data set, with fittedWeibull model.
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needing treatment at the start of the programme would
be about 8.5%, whereas a more ambitious programme,
aiming to recruit those expected to die within 6 years
would categorise 43.5% of the HIV-infected population
as in need of treatment at baseline. However, a
programme aiming to recruit only those within a year of
death would have to grow very fast: within 5 years it
would need to quadruple in size, reaching 36.5%, to keep
up with this modest aim, whereas a successful pro-
gramme aiming to treat those 6 years from death from
the very start would only need to grow by 40% to reach
59% coverage of all infected persons over the course of
5 years.
Estimating ART need in Tanzania, 2007–2010: a worked
example
An illustrative application of the proposed method to
estimate the theoretical need for ART in Tanzania
between 2007 and 2010 is shown in Table 5. The basic
input data are taken from the 2007 DHS survey of
Tanzania (DHS, 2011), which took place 3 years after the
start of Tanzania’s national ART programme, launched in
2004. The mid-year population estimate for Tanzania in
2007 is based on the UN population division medium
estimate (http://esa.un.org/wpp/unpp/panel_popula-
tion.htm; accessed 4 January 2012). For ages 15–49, age-
specific HIV prevalence estimates were taken from the
DHS. We assumed that prevalence at older ages declined
by 12% for each 5-year age group, but then pro-rated
prevalence in all these age groups to ensure that HIV
prevalence in the whole 50+ age group was lower than
prevalence at ages 15–49 by a factor of 1.7 – this overall
age relationship is based on observed prevalence in the
Kisesa cohort study (Mwita et al. 2007) in Northern
Tanzania, and is used by the National AIDS Control
Programme as a standard estimate for HIV prevalence at
ages 50 + in the decade 2000–2010 (Ministry of Health,
2011). This effectively implies zero HIV prevalence at ages
80 and over.
Applying the model to the estimated 1.121 million HIV-
infected adults in Tanzania suggests that if 2007 had been
the initial year of the ART programme with the aim of
reaching those infected persons expected to die within
3 years, the number needing treatment would be 293 000.
Based on a CD4 threshold of 200 for treatment initiation,
the SPECTRUM model estimate for treatment need in
2007 for Tanzania is 279 000 (J. Stover, personal com-
munication ), about 5% lower than the estimate based on
this simple model.
Since 2007 was actually year 3 of the programme, our
model indicates that a theoretical target of a totally
successful programme would be 482 000. The reported
cumulative number of patients recruited to the treatment
programme by 2007 was in fact 164 000, much lower than
any of these theoretical targets (Ministry of Health, 2011).
Table 4 Model proportion needing treatment by age group and programme year, defining treatment need as proportion expected to die
within 3 years in the absence of treatment
Current age group
Years since start of treatment programme
0 1 2 3 4 5
15–19 0.091 0.112 0.124 0.131 0.134 0.135
20–24 0.153 0.196 0.230 0.258 0.282 0.300
25–29 0.203 0.259 0.306 0.347 0.383 0.414
30–34 0.245 0.309 0.364 0.413 0.456 0.493
35–39 0.282 0.353 0.415 0.469 0.517 0.558
40–44 0.315 0.392 0.459 0.517 0.568 0.612
45–49 0.344 0.427 0.498 0.559 0.611 0.656
50–54 0.371 0.459 0.533 0.595 0.648 0.694
55–59 0.396 0.487 0.563 0.627 0.680 0.725
60–64 0.419 0.513 0.591 0.655 0.709 0.753
65–69 0.441 0.538 0.616 0.681 0.734 0.777
70–74 0.461 0.560 0.639 0.704 0.756 0.799
75+ 0.496 0.602 0.682 0.745 0.795 0.835
All age proportion given average HIV prevalence by age in ALPHA sites
Males 0.262 0.327 0.382 0.430 0.472 0.508
Females 0.228 0.284 0.333 0.374 0.410 0.441
Both sexes 0.240 0.299 0.350 0.394 0.432 0.465
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We can use Eqn 5 to investigate whether the programme
is catching up on targets in subsequent years. Putting
T(z) = 0, T(z + 1) = 293, T(z + 2) = 365, T(z + 3) = 428
and given R(y) = 164, the reduced needs in 2008 and 2009
would be given by:
Rð2008Þ ¼ Rðy þ 1Þ
¼ ð293 164Þ  293þ ð164 0Þ  365
293
¼ 334 thousand
Rð2009Þ ¼ Rðy þ 2Þ
¼ ð365 334Þ  365þ ð334 293Þ  428ð365 293Þ
¼ 400 thousand:
The reported cumulated number recruited to the
Tanzanian ART programme by 2008 was 283 000
(Ministry of Health, 2011), so by 2008, the programme
did not manage to catch up even with the reduced target
number implied by this model. However, by 2009, the
programme had managed to recruit a cumulated total of
456 000 (Ministry of Health, 2011), exceeding the
reduced target number of 400 000 for 2009. The
SPECTRUM estimates of ART need in 2008 and 2009,
respectively, were 290 000 and 316 000, which would
seem rather low, given actual programme recruitment,
although the official recruitment figures do not indicate
the number currently receiving treatment.
Estimating ART need in the ALPHA study sites
Table 6 shows the results of applying this model to the
actual age distribution of the infected population in each
study site, by gender, to estimate the minimum initial need
in 2004, close to the start year for most national
programmes, and the maximum theoretical need in 2008,
if programmes had successfully recruited all those expected
to die within 3 years. Estimates are not available for
Manicaland for 2008, as data from that site were only
contributed to the pooled data set up to 2005. The overall
proportions needing treatment are higher in the actual
surveillance populations than in the ‘all age’ row in
Table 4, because the average age distribution of infected
persons in the pooled data set in the pre-ART era was
younger than the distribution of infected persons in the
surveillance sites in 2004 and 2008. In all sites for both
years, the proportion of HIV-infected males needing
treatment is higher than the proportion of females needing
treatment, reflecting the older age distribution and higher
mortality of the men. Karonga and Kyambuliwa have a
slightly higher overall need than the other sites. The actual
proportions on treatment in each site are discussed in
papers elsewhere in this volume (Alison et al. 2012).
Figure 3 shows information about the age–gender dis-
tribution of people needing treatment in four of the sites
in 2004 and in 2008. The years were chosen to contrast
the situation at the start of the programmes in populations
that were treatment naive, and 4 years later when successful
programmes should have built on earlier achievements. The
proportions from the model presented in Table 4 are
applied to the actual numbers of HIV positive persons
observed in the cohort at the start of these years, assuming
that prevalence in residents of unknown status is the same
as those whose status has been measured. The number in
need of ART treatment is shown by the dark parts of the
bars, and the total height of the stacked bar represents the
number of HIV infected, so that the pale part of the stacked
bar represents the rest of the HIV-infected people in each
age group, who are not classified as needing treatment, but
who should be receiving monitoring care with regular
checks on CD4 counts and disease stage.
Table 6 Model predictions of the proportions of HIV infected and overall number needing Ante-Retroviral Treatment in selected calendar
years in five ALPHA network study sites
Site
Predicted proportion (and number) of HIV infected needing treatment
Ratio of treatment need in
2008–2004
Year
Proportion Number
2004 2008
Males Females Males Females
Karonga 0.285 (157) 0.245 (211) 0.525 (308) 0.472 (434) 1.9 2.0
Umkhanyakude 0.260 (857) 0.230 (1590) 0.489 (1296) 0.441 (2855) 1.9 1.7
Kisesa 0.260 (101) 0.234 (115) 0.464 (132) 0.438 (180) 1.8 1.5
Kyambaliwa 0.276 (74) 0.241 (91) 0.521 (149) 0.458 (204) 1.9 2.1
Manicaland 0.277 (75) 0.264 (150)
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Figure 3 Number of HIV positive persons needing treatment or needing care by study site and gender at start of anti-retroviral therapy
availability in 2004 and in growing programmes by 2008.
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Comparing the age-specific and total numbers across the
study sites, the following features emerge: overall, more
women than men need treatment, as there are higher
numbers of infected women. The sex ratio F:M among
those needing treatment ranges from around 1.2 (in Kisesa,
Karonga and Kyambuliwa) to 1.9 (in Manicaland and
Umkhanyakude) and rises slightly over time. However,
the excess in the number of women needing care rather
than treatment is even larger than the corresponding
number for men (sex ratios range from 1.5 in East
African sites to 3.2 in Southern African sites), as lower
proportions of women need treatment because their age
distributions are younger. There is a clear peak age for
treatment need in women at age 30–34 in all sites, whereas
for men, treatment need is more evenly spread across
the age groups, with a slightly older peak spread over
ages 35–44.
Growth in numbers of people needing treatment
differs from growth in the proportions needing treatment
because of natural and migration-driven changes in the
study populations. In Karonga and Kyambuliwa numbers,
needing treatment increase faster than proportions because
of increases in total numbers infected of the order of 10%
over the 4-year period, and in Karonga, this increase is
in part fuelled by the overall growth of the population in
the study site.
Discussion
The method provides a simple alternative to epidemic
projection models for estimating age-specific ART need
in populations in any year that age-specific HIV preva-
lence is known or has been estimated. It uses age-specific
mortality patterns recorded for HIV-infected persons in
the era before widespread availability of ART to deter-
mine the proportion of HIV-infected persons who are
expected to die within a specified number of years – this
proportion represents the deaths that it is hoped to avert
by enrolling people on the ART programme. The method
does not require knowledge of HIV incidence rates in the
population, and can be applied in sub-national popula-
tions where prevalence may be determined by local
migration patterns as well as by incidence rates. It is well
known that the rate of progression from infection to
death increases steadily with age (Todd et al. 2007) –
this method alerts us to the corresponding importance of
age as a determinant of ART need, a factor that tends to
be overlooked if it is assumed that a fixed proportion of
treatment naive HIV-infected people have CD4 counts
low enough to qualify for ART.
This estimation technique can be applied in popula-
tions with large numbers of people already on treatment,
who are included in the HIV prevalence estimate. The
outputs represent those who should be currently receiv-
ing HIV treatment, whereas some national programmes
only report cumulative numbers who have ever received
ART. It is assumed that anyone already receiving
treatment belongs to the treatment need group defined
on the basis of mortality expectations, and this simple
model has not yet been refined to handle changes over
time in the criteria for admission of people to the ART
programme.
The age-specific mortality schedule used in this article
is based on all cause mortality of the HIV infected in the
pre-treatment era. Had we adjusted for non-AIDS deaths
among the HIV infected, our estimates of the proportion
needing treatment (expected to die in the next 3 years)
would have been approximately 2% lower at ages 15–29
and 5% lower at ages 50+, based on ‘net’ mortality
patterns described previously in these populations
(Marston et al. 2007).
Another important assumption concerns the
approximate equality in mortality between infected
persons already on treatment and those judged as not yet
needing treatment. This assumption can be looked at in
terms of long-term goals of a treatment programme – if
the mortality of those classified as not yet needing
treatment is appreciably higher than the mortality of
those on treatment, this suggests that too many high risk
persons are left in the group designated as not yet in
need of treatment, setting a more inclusive target for
acceptance onto treatment would lower mortality among
the group designated as not yet needing treatment.
Conversely, if mortality is much higher amongst those on
treatment, this suggests that the available treatment is
not effective enough to warrant the inclusion of such a
large fraction, as there is no overall mortality gain from
their inclusion.
As evidence from ART clinics suggests that mortality
may be very high in the first year following treatment
initiation, it will be important to measure mortality of the
two groups over a period of time commensurate with the
mortality prevention goals of the selection criteria – e.g. if
the CD4 count threshold for recruitment onto treatment is
supposed to be equivalent to preventing expected AIDS
deaths in the next 3 years, then the programme would have
to have recruited a proportion of infected people equiva-
lent to theoretical need at baseline + 3 years (about 35%)
to ensure a balance of long- and short-term ART users in
whom mortality effects of treatment could be reasonably
assessed. One reason that we might expect high mortality
for those on ART is that patients who fail ART may not
be moved quickly to a secondary treatment regime, and
remain on failing regimens for prolonged periods that
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would expose them to a substantially increased risk of
death. Programmes with high levels of treatment discon-
tinuation would also end up with higher mortality amongst
the ever-treated than is assumed in this method.
If the long-term mortality of those receiving ART
treatment turns out to be lower than mortality of those not
yet needing treatment, this method would consistently
under-estimate future treatment need, if mortality of those
on treatment turns out to be higher than mortality of those
classified as not yet needing treatment future treatment
needs will have been over-estimated.
In small geographically defined populations, prevalence
is determined as much by movement of infected people into
and out of the region as by incidence amongst the
uninfected and deaths of infected persons (Mwita et al.
2007). In this situation, the methods presented here will be
valid, provided that migration is not related to treatment
seeking – i.e. provided that in-migration is not an influx of
people seeking treatment in the locality or that out-
migration is not motivated by the necessity to seek
treatment outside the locality. Where prevalence estimates
are themselves subject to uncertainty – e.g. due to missing
data as a result of test refusals, estimates of ART need will
also be affected (Ba¨rnighausen et al. 2011).
We have illustrated the estimation procedures above in
the same HIV cohort studies that supplied the data for
calculating the age-specific mortality rates for those
infected with HIV. Some of these studies have now
achieved very high levels of HCT, and have representative
data on CD4 counts in the general population, i.e. direct
measures of ART need (Malaza et al. 2011). However, the
real power of the method will lie in its application in
national and sub-national populations where HCT service
use is far from universal, but where surveillance data are
available – such as anonymous HIV testing in the context
of a nationally representative survey like the DHS (DHS,
2011) – and can be used to obtain an age distribution of
HIV-infected persons.
One advantage of the method is that if alternative
methods are developed to select people for treatment – e.g.
relying on viral load or some new type of clinical observa-
tion, rather than CD4 count – these could also be described
in terms of years of AIDS-related mortality that we seek to
avert. The simple method allows a health planner to
envisage the size of a local ART programme that would be
required, given a desired impact in terms of average years
of life gained by HIV-infected persons.
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